First mover advantage in multi-billion dollar Mexico market and positioned for $750b market via export.
Strong, collaborative relationship with institutions leading the design of Mexico's cannabis regulatory framework.
Strong product suite: 53 new cannabinoid-based products in late-stages of development, ready for launch.
Large-scale GMP pharmaceutical production.
Execution skills and scientific expertise to capitalize on medicinal cannabis.
20+ Years of pharma experience at the highest industry standards, domestically and internationally.